Index

α-adrenergic receptors 183, 341–3, 432–3
α-noradrenergic receptors 200
ABA see applied behavioral analysis
abbreviated new drug applications (ANDA) 40, 42–3, 46–8
Aberrant Behavior Checklist (ABC) 202–3, 352
absorption 52–3, 302–4, 305
abuse potential
antidepressants 116
anxiolytics 324–5
psychostimulants 88–9
ACE see angiotensin converting enzyme
acute mania 221, 243
see also manic episodes
ADHD see attention-deficit/hyperactivity disorder
adherence see patient adherence/compliance
ADME studies see pharmacokinetics
adrenergic agents 341–64
beta-blockers 343–4, 355–61
case histories 344–5
chemical properties and clinical pharmacology 343–4, 356
clonididine 341–9, 352–5
contraindications 346, 352, 359
dosing and administration 342–5, 354–5, 360–1
drug interactions 360–1
guanfacine 341–4, 346, 349–55
indications 341, 346, 356–9
overdose 354
rebound effects 354
side-effects 347, 351–4, 360
α-adrenergic receptors 183, 341–3, 432–3
adulterants, generic drugs 43
advertising campaigns 34, 44
age-appropriate assessments 400–2
aggressive behavior
adrenergic agents 356–7
anticonvulsants 266, 273
anxiolytics 313–14
lithium 238–9
preschool psychotropic medication use 407, 410
psychostimulants 92–3
agitation 356–7
akathisia 358–9
alcohol dependence/abuse 367, 373
allergic reactions 41
alopecia 268–9
alpha-agonists
attention-deficit hyperactivity disorder 90–2
combination pharmacotherapy 432–3
pharmacoepidemiology 11, 14–15, 18
Alzheimer’s disease (AD) 188–9, 194–5
analgesia 381
ANDA see abbreviated new drug applications
angiotensin converting enzyme (ACE) inhibitors 243
angiotensin receptor blockers (ARB) 243
antibiotics 244
440  Index

anticholinergic effects  antidepessants 113–14
  antidepressants 113–14
  antipsychotics 185
  anxiolytics 323, 331
anticipatory anxiety 312–13
anticonvulsants 261–99
  carbamazepine 262, 264, 271–5, 287
  chemical properties and mechanisms
    of action 261–4, 272, 275–6,
    279–80, 285
  clinical pharmacology 262–3
  contraindications 270, 274, 278–9
  divalproex sodium 261–71, 287
  dosing and administration 271, 275,
    279, 284–6
  drug interactions 264, 276, 277–8,
    281–2, 286
  drug monitoring 264
  gabapentin 263–4, 271, 284–5, 288
  indications 265–7, 272–3, 277,
    280–1, 284–6
  lamotrigine 263–4, 271, 279–84, 287
  maintenance therapy 281
  oxcarbazepine 263–4, 271, 275–9,
    287
  preschool psychotropic medication
    use 406
  side-effects 267–71, 273–5, 278–9,
    282–6
  topiramate 263–4, 271, 285–6, 288
  toxicity 267–8, 270–1, 274–5, 279,
    283–4
see also mood stabilizers
  antidepressants 105–29, 131–54
  abuse potential 116
  anxiety disorders 308, 310
  attention-deficit hyperactivity
    disorder 90
  chemical properties 105–6, 117–18
  clinical pharmacology 53–4, 57–9
  combination pharmacotherapy 421,
    429–30, 433–4
  comorbidities 109, 110
  concomitant psychotropic medication
    16
  context and historical perspective
    105, 117
  dosing and administration 132
  drug interactions and
    contraindications 116
drug monitoring 147, 149
  historical perspectives 2–3
  indications 105, 106–12, 117, 122–3,
    131, 134–45
  initiation and titration 112–13, 133–4
  lithium augmentation 237–8
  long-term usage 148–9
  maintenance therapy 112–13
  off-label use 12–13, 28, 30–2
  overdose 115–16, 122
  pharmacoepidemiology 11–13, 16
  pharmacokinetics 106, 131–4
  preschool psychotropic medication
    use 407
  side-effects 113–15, 121–3, 133–4,
    146–9
  suicidality 147–8
  tests and examinations 112–13
  withdrawal symptoms 112–13, 120,
    145
see also individual drug class; novel
  antidepressants
antihistamine effects of antidepressants
  114
  antihistamines 303–4, 305–13, 317–18,
    321, 323–6, 328–32
  antipsychotics 181–219
    atypical antipsychotics 181–3,
      186–212, 426–7
    bipolar disorder 235, 237
    chemical classes 182
    chemical properties 182–3
    clinical pharmacology 53, 58, 184,
      196, 200, 206, 208–10
    clinical trials 186–213
    combination pharmacotherapy
      421–2, 424–7
    concomitant psychotropic medication
      16
    dosing and administration 198–204
    drug interactions 245
    ethical issues 212–13
    indications and efficacy 181–2,
      184–5, 186–212
    off-label use 32
    pharmacoepidemiology 13–14, 16
    preschool psychotropic medication
      use 406–7
    side-effects 181, 183–4, 185–6, 197,
      202, 204–5, 358–9
anxiety disorders
adrenergic agents 357–8
anticonvulsants 267
antidepressants 105, 107, 108–11, 117, 131, 137, 139–46
anxiolytics 306–13, 320
clinical pharmacology 51
combination pharmacotherapy 421–2, 431, 433–4
comorbidities 92, 110, 226
complementary and alternative medications 376, 378, 388
memantine 368
novel antidepressants 161, 165, 172, 175
preschool psychotropic medication use 411–15
psychostimulants 77–8
riluzole 370
topiramate 372–3
see also individual disorders
anxiolytics 301–40
abuse and dependence 324–5
antihistamines 303–4, 305–13, 317–18, 321, 323–6, 328–32
anxiety disorders 306–13, 320
behavioral disorders 313–15
chemical properties and mechanisms of action 301–5
clinical pharmacology 302–5
contraindications 320–1, 331
dosing, preparations and costs 325–30
drug interactions 326
indications 305–20
maintenance therapy 325, 329–30
melatonin 318
overdose 324
side-effects 307, 321–4
sleep disorders 314–20
tic disorders 314
withdrawal symptoms 331, 332
appetite suppression 1
applied behavioral analysis (ABA) 403, 407
ARB see angiotensin receptor blockers
area under the plasma concentration-time curve (AUC) 55
ASD see autism spectrum disorders
Asperger’s disorder 348, 406–8
see also autism spectrum disorders; pervasive developmental disorders
asthma 78–9
at-risk populations 212–13
attention-deficit/hyperactivity disorder (ADHD)
adrenergic agents 341, 344–7, 349–56
anticonvulsants 266, 273, 359
antidepressants 105, 110
antipsychotics 185, 195, 209–11
anxiolytics 313–15
behavior rating scales 82–3
cardiovascular safety issues 86–7, 91–2
clinical pharmacology 51, 54, 56
combination pharmacotherapy 421–2, 426–7, 429, 431–3
comorbidities 77–8, 92–3, 110, 225–6, 234, 407, 422, 426–7, 429, 431
complementary and alternative medications 374, 377
diagnosis 228
dosing and administration 79–84
growth suppression 88
historical perspectives 2
long-term efficacy studies 76–9
multimodality treatment 76–9
neuroimaging studies 65, 68–72
nonstimulant medications 11, 89–92, 422, 427–8, 432–3
novel antidepressants 160–1, 172
off-label use 28, 33–4
pharmacoepidemiology 8–11, 14, 15
pharmacogenetics 93–4
preschool psychotropic medication use 404, 407–9, 413
psychostimulants 9–11, 65–6, 68–94
short-term efficacy studies 72–5
side-effects and adverse outcomes 84–9
substance abuse and diversion 88–9
Index

atypical antidepressants see novel antidepressants
atypical antipsychotics 181–3, 186–212, 426–7
atypical depression 118–19
AUC see area under the plasma concentration-time curve
autism spectrum disorders (ASD)
anticonvulsants 266
antipsychotics 185
comorbidities 407
complementary and alternative medications 374
memantine 369
off-label use 32, 34
opiate antagonists 366
pharmacoepidemiology 14, 16
preschool psychotropic medication use 406–8, 413
secretin 371
see also pervasive developmental disorders
Bcl-2 223
bedwetting see enuresis
behavior rating scales 82–3
behavior therapy 76–9
behavioral disorders
adrenergic agents 356–7
anticonvulsants 266, 273
antipsychotics 185, 188, 204–5
anxiolytics 313–14, 323, 330–1
lithium 231, 238–9
novel antidepressants 168
see also disruptive behavioral disorders
Best Pharmaceuticals for Children Act (BPCA) 44–5, 48
beta-blockers 343–4, 355–61
bilirubin 56
bioavailability
anticonvulsants 262–3
clinical pharmacology 52–3, 55, 58
lithium 240
novel antidepressants 170–1
bioequivalence data rule 40, 42–3
bipolar disorder
anticonvulsants 265–6, 272–3, 277, 280–1, 285–6
antidepressants 147
antipsychotics 187, 190–2, 194–5, 200, 202, 206–13
at-risk populations 230–2, 234–5
chronicity and cycling 228–9
clinical characteristics 226–7
clinical trials and studies 232–3
combination pharmacotherapy 422–9
comorbidities 92, 225–6, 229, 234, 426–7, 429
depressive episodes 228–9, 236, 280–1
diagnosis 224–5, 228
DSM-IV criteria 226–9, 232
epidemiology 224, 225
historical perspectives 1
lithium 221, 222, 232–7
maintenance therapy 236–7, 281
mania and hypomania 224–35
memantine 368
mixed states 229, 233–5
off-label use 27, 34
pharmacoepidemiology 14–16
preschool psychotropic medication use 410–11, 413
psychotic episodes 237
sub-threshold 229–30
symptomatology 227–8
topiramate 372
birth defects 245–6, 270, 278–9
black box warnings 242
bleeding 147
body size and composition 55–6, 59–60
bone density effects 269
BPCA see Best Pharmaceuticals for Children Act
bradycardia 344, 347, 350, 360–1
bulimia nervosa
anticonvulsants 286
complementary and alternative medications 378
novel antidepressants 168
opiate antagonists 367
bupropion 157–62
Index 443

caffeine 85, 244
calcium-channel blockers 244
CAM see complementary and alternative medications
carbamazepine 244–5, 262, 264, 271–5, 287
cardiovascular effects
  anticonvulsants 269
  antidepressants 114–15, 122
  antipsychotics 186
  lithium 249–50
  off-label use 28
  preschool psychotropic medication use 405
  psychostimulants 86–7, 91–2
CASL see continuous arterial spin labeling
CBT see cognitive behavioral therapy
CD see conduct disorders
CDCL see Child Behavior Checklist
CDRS-R see Children’s Depression Rating Scale-Revised
central nervous system (CNS) effects 268, 273
CGI see Clinical Global Impressions
Child Behavior Checklist (CBCL) 400
child parent psychotherapy (CPP) 412
Children’s Depression Rating Scale-Revised (CDRS-R) 136, 171, 280–1
Children’s Global Assessment Scale 425
cholesterol 269
chronicity 228–9
clearance
  anticonvulsants 262–3
  antidepressants 132–3
  clinical pharmacology 53–4, 55, 59–60
  lithium 240
Clinical Global Impressions (CGI)
adrenergic agents 352
  anticonvulsants 267, 277, 281
  antipsychotics 203, 207
  combination pharmacotherapy 425
  lithium 234
  memantine 369
clinical pharmacology 51–63
  absorption and bioavailability 52–3, 55, 58
  anticonvulsants 262–3
  antidepressants 53–4, 57–9
  antipsychotics 53, 58, 184, 196, 200, 206, 208–10
  anxiolytics 302–5
  body size and composition 55–6, 59–60
  clearance 53–4, 55, 59–60
  developmental processes 55–6
  distribution 53
  dosing and administration 55–60
  drug interactions 58–9
  elimination half-life 54
  metabolism 56–8
  pharmacogenetics 56–8
  pharmacokinetics 52–5, 59–60
  CLOCK protein 224
  clonidine 341–9, 352–5
CNS see central nervous system
cognitive behavioral therapy (CBT)
  anxiety disorders 108–9, 141, 142–5
  major depressive disorder 134–5, 139
  novel antidepressants 171–2
  preschool psychotropic medication use 403, 411–12
  cognitive impairment 330
combination pharmacotherapy 421–38
  adrenergic agents 347
  attention-deficit/hyperactivity disorder 421–2, 426–7, 429, 431–3
  bipolar disorder 234–5, 237–8, 422–9
  major depressive disorder 429–31
  obsessive compulsive disorder 433–4
  pervasive developmental disorders 434
  pharmacoepidemiology 15–16, 18
  thyroid augmentation 428–9
  tic and Tourette’s disorder 434
  weight gain 426–7
complementary and alternative medications (CAM) 373–81
  clinical pharmacology 58
  Ginkgo biloba 375, 381
  melatonin 381–3
  novel antidepressants 174–5
  omega-3 fatty acids 175, 383–4
  St John’s wort 58, 175, 384–7
  valerian 387–8
Index

compliance see patient adherence/compliance
conduct disorders (CD)
  anticonvulsants 267, 273
  antipsychotics 185, 188, 191, 193, 196, 208, 211
  anxiolytics 313–14
  comorbidities 77–8, 92–3, 226
  lithium 221, 238–9
  preschool psychotropic medication use 409–10, 413
  constipation 113–14
  continuous arterial spin labeling (CASL) technique 72
  continuous performance test (CPT) 69–71
contraindications
  adrenergic agents 346, 352, 359
  anticonvulsants 270, 274, 278–9
  antidepressants 116
  anxiolytics 320–1, 331
  combination pharmacotherapy 435
  complementary and alternative medications 376–81, 383–4, 386–8
  lithium 242–3
  memantine 369
  novel antidepressants 157, 159, 162, 164, 166, 170, 173–4
  opiate antagonists 367–8
  riluzole 371
  secretin 372
  topiramate 373
  corticosteroids 78–9
  cost-effectiveness 26, 30–1
CPP see child parent psychotherapy
CPT see continuous performance test
  cycling 228–9, 428–9
CYP see cytochrome P450
cystic fibrosis 422
  cytochrome P450 (CYP) enzymes 52, 54, 56–9, 174
D-cycloserine (DCS) 376
DBD see disruptive behavior disorders
demographic data 9, 12–16
dependence potential 324–5
depression
  bipolar disorder 228–9, 236, 280–1
  clinical pharmacology 51
  combination pharmacotherapy 421
  complementary and alternative medications 382–6
  lithium 237–8
  memantine 368
  off-label use 32
  pharmacoepidemiology 13
  preschool psychotropic medication use 413
  see also major depressive disorder
dermatological effects 273–4, 282–3
  desmopressin 244
  desvenlafaxine 158–9, 173–4
devolutional disorders
  clinical pharmacology 55–6
  off-label use 28–9
  see also autism spectrum disorders; pervasive developmental disorders
  DHA see docosahexaenoic acid
diabetes mellitus 2
diagnostic blood tests 112–13
dietary supplements see complementary and alternative medications
discontinuation see withdrawal symptoms
disinhibition 323, 330–1
disruptive behavior disorders (DBD)
  antipsychotics 188, 204–5
  combination pharmacotherapy 426–7
  comorbidities 426–7
  preschool psychotropic medication use 409–10, 413
  see also conduct disorders;
oppositional defiant disorder
distribution 53, 262–3
diuretics 243
divalproex sodium 231, 234, 261–71, 287, 423–5
diversion of psychostimulants 88–9
dizziness 332
docosahexaenoic acid (DHA) 383–4
dopamine
  antipsychotics 182, 206
  plasticity 33
d psychostimulants 67, 68, 93–4
dosing and administration
  adrenergic agents 342–5, 354–5, 360–1
  anticonvulsants 271, 275, 279, 284–6
antidepressants 132, 133–4, 138, 146
antipsychotics 198–204
anxiolytics 325, 327–30
body size and composition 55–6, 59–60
clinical pharmacology 55–60
complementary and alternative medications 376–81, 383–4, 386, 388
developmental processes 55–6
drug interactions 58–9
lithium 239–42
memantine 369
novel antidepressants 158–9, 163, 165, 167, 170–1, 173–4
off-label use 32–3
opiate antagonists 367
pharmacogenetics 56–8
preschool psychotropic medication use 404–5
psychostimulants 79–84
riluzole 370–1
secretin 371
topiramate 373
see also overdose
drug interactions
adrenergic agents 360–1
anticonvulsants 264, 276, 277–8, 281–2, 286
antidepressants 116
anxiolytics 326
clinical pharmacology 58–9
combination pharmacotherapy 434–5
complementary and alternative medications 387–8
lithium 243–6
novel antidepressants 157, 159, 162, 169–70, 174
off-label use 35
drug monitoring
anticonvulsants 264
antidepressants 147, 149
lithium 239–43
preschool psychotropic medication use 404–5
dry mouth 113–14
dysthymia 413
duloxetine 158–9, 161–4
dyskinesias 323, 331
see also tic disorders
early-onset schizophrenia (EOS) 196–201
eating disorders
anticonvulsants 286
complementary and alternative medications 378
novel antidepressants 168
opiate antagonists 367
EEG see electroencephalography
eicosapentaenoic acid (EPA) 383–4
EKG see electrocardiography
elated mood 227
electrocardiography (EKG) 87, 91–2, 405
electroencephalography (EEG) 65, 69
elimination half-life 54, 222, 262–3
endocrine effects
anticonvulsants 269, 274, 278–9
lithium 242, 243, 248–50
enuresis 110–11
EOS see early-onset schizophrenia
EPA see eicosapentaenoic acid
epilepsy 261
EPS see extrapyramidal side-effects
ERP see event-related potentials
ethical issues 212–13
event-related potentials (ERP) 65, 69–70
excipients 41
extrapyramidal side-effects (EPS)
antipsychotics 181, 183–4, 185–6, 202, 204
preschool psychotropic medication use 407
family therapy 142
fMRl see functional magnetic resonance imaging
follow-up practices 36
food and bioavailability 52, 170–1
fragile X syndrome 33
free play 400–1
free radical scavengers 381–3
functional magnetic resonance imaging (fMRI) 65, 70–2, 280
GABA see gamma amino butyric acid
GABAergic agonists 4
gabapentin 263–4, 271, 284–5, 288
GAD see generalized anxiety disorder
Index

gamma amino butyric acid (GABA) 264, 272, 284–5
gastrointestinal (GI) effects anticonvulsants 267, 274
anxiolytics 323, 331
lithium 247
generalized anxiety disorder (GAD) antidepressants 142–4
anxiolytics 306–7, 320
complementary and alternative medications 388
novel antidepressants 161, 172
preschool psychotropic medication use 412–14
riluzole 370
generic drugs 39–50
ANDA requirements 40, 42–3, 46–8
basic requirements 40–1
Best Pharmaceuticals for Children Act 44–5, 48
context and regulatory factors 39–48
excipients 41
historical perspective 43–4
pediatric assessment of adult drugs 43–4, 46–8
Pediatric Research Equity Act 45–6, 48
pharmacokinetics and pharmacodynamics 39–41, 48
use patterns 39–40

genetics see pharmacogenetics
GFR see glomerular filtration rate
GI see gastrointestinal
Ginkgo biloba 375, 381

ginseng 377

glomerular filtration rate (GFR) 53, 243–4
glucuronidation 56
glutamate-modulating agents 369–71
glycogen synthase kinase 3β (GSK-3β) 222–3, 248
Go/No-Go tasks 70–1
grandiosity 227–8
grey baby syndrome 51
growth suppression 88
GSK-3β see glycogen synthase kinase 3β

guanfacine 341–4, 346, 349–55
haloperidol 32, 245
Hamilton Rating Scales (HAM) anticonvulsants 280
antidepressants 136–7
combination pharmacotherapy 430
complementary and alternative medications 385
riluzole 370
HBQ see Health and Behavior Questionnaire
HDAC see histone deacetylase
HDL-C see high-density lipoprotein
headache 111
Health and Behavior Questionnaire (HBQ) 400
hematological effects 270, 274
hepatotoxicity 267–8, 274
herbal medications see complementary and alternative medications
high-density lipoprotein (HDL-C) 269
histamine 183, 200
histone deacetylase (HDAC) inhibition 264
historical perspectives 1–5, 43–4
hospitalization 26
Hypericum perforatum 58, 175, 384–7
hyperprolactinemia 186
hypertensive crisis 121
hypomania antidepressants 147
bipolar disorder 229–31
combination pharmacotherapy 423
hyponatremia 277
hypotension 169, 344, 347
IBS see irritable bowel syndrome
impulse-control disorders 109–10
in utero exposure see pregnancy;
teratogenicity
informed consent 36
inositol 378
insomnia anxiety 314–15, 331
complementary and alternative medications 382, 387–8
novel antidepressants 165–7
intelligence quotient (IQ) 274
international patterns of use 17–18
interpersonal therapy 134–5
IQ see intelligence quotient
irritability 227–8, 407, 410
irritable bowel syndrome (IBS) 111–12
jaundice 56
K-SADS see Schedule for Affective Disorders and Schizophrenia
kava kava 379
kidney function 242, 243, 248, 250
LABA see long-acting beta-agonists labeling
generic drugs 43–4, 48
lithium 242
psychostimulants 85–6
see also off-label use
lactose intolerance 41
lamotrigine 263–4, 271, 279–84, 287
LDL-C see low-density lipoprotein
legislation and regulatory factors 25–7, 31–4, 39–48
lightheadedness 332
lactose intolerance 41
lithium 221–59
acute mania 221, 243
aggressive behavior 238–9
bipolar depression 236
bipolar disorder 221, 222, 232–7
clinical pharmacology 222, 240–1
clinical trials and studies 232–3
combination pharmacotherapy 423–5, 429–31
conduct disorder 221, 238–9
dosing and drug monitoring 239–43
drug interactions and contraindications 242–6
future directions 239
maintenance therapy 236–7
mania and mixed episodes 233–5
mechanisms of action 222–4
pregnancy and women’s health 245–6
psychotic episodes 237
severe mood dysregulation 238
side-effects 221, 241, 246–50, 359
toxicity 246–7
unipolar depression 237–8
liver function 267–8, 274
long-acting beta-agonists (LABA) 78–9
long-term usage 3
antidepressants 148–9
off-label use 27–8
pharmacoeconomics 10–11
psychostimulants 76–9
low-density lipoprotein (LDL-C) 269
MADRS see Montgomery–Asberg Depression Rating Scale
magnetic resonance imaging (MRI) 65, 70–2, 280
major depressive disorder (MDD) antidepressants 12, 105–8, 118–20, 131, 134–9, 144
combination pharmacotherapy 15, 429–31
comorbidities 92, 431
complementary and alternative medications 378, 380
preschool psychotropic medication use 410, 413
major depressive episodes (MDE) 228
manic episodes antidepressants 147
combination pharmacotherapy 423
lithium 221
off-label use 30
see also bipolar disorder
MAOI see monoamine oxidase inhibitors
marketing campaigns 34, 44
MDE see major depressive episodes medication management 76–9
melatonin 318, 381–3
memantine 368–9
menopause 377
menstrual disorders 269
metabolism 56–8
adrenergic agents 343
anticonvulsants 262–3, 268, 274
antidepressants 106
antipsychotics 184
anxiolytics 302–4, 305
metronidazole 244
MHD see monohydroxy derivatives
448 Index

migraine 111, 161
mirtazapine 158–9, 161, 164–6
mixed states 229, 233–5
monoamine oxidase inhibitors (MAOI)
  chemical properties 117–18
  clinical pharmacology 58
  drug interactions 245
  indications 117
  initiating, maintaining and withdrawing treatment 120
  overdose 122
  side-effects 121–2, 156
  monohydroxy derivatives (MHD) 276, 277, 279
  Montgomery–Asberg Depression Rating Scale (MADRS) 137, 280, 370
mood disorders
  antipsychotics 193
  novel antidepressants 168
  pharmacoepidemiology 16
  riluzole 370
mood stabilizers
  combination pharmacotherapy 421, 423–6, 427–8
  pharmacoepidemiology 15, 18
  preschool psychotropic medication use 406
  see also lithium
multimodality treatment of ADHD 76–9
multiple class studies 17
N-acetylcysteine (NAC) 379
N-methyl-D-aspartic acid (NMDA) receptors 264
NAC see N-acetylcysteine
narcolepsy 1
neural tube defects (NTD) 270
neuroimaging studies 65, 67–72, 280
neuroleptic malignant syndrome (NMS) 186
neurologic examinations 159, 345
neurologic side-effects 247, 250
new drug applications (NDA) 40, 42–3
night terrors 319
NMDA see N-methyl-D-aspartic acid
NMS see neuroleptic malignant syndrome
NNH see number needed to harm
NNT see number needed to treat
nonsteroidal anti-inflammatory drugs (NSAID) 244
nonstimulant ADHD medications 11, 89–92, 422, 427–8, 432–3
α-noradrenergic receptors 200
norepinephrine 67, 93–4, 105–6
novel antidepressants 155–79
bupropion 157–62
chemical properties 157, 162–4, 166, 170, 173
complementary medications 174–5
desvenlafaxine 158–9, 173–4
dosing and administration 158–9, 163, 165, 167, 170–1, 173–4
drug interactions and contraindications 157, 159, 162, 164, 166, 169–70, 173–4
duloxetine 158–9, 161–4
indications and efficacy 155–7, 160–1, 163, 165–8, 171–2, 174
mirtazapine 158–9, 161, 164–6
pharmacokinetics and pharmacodynamics 157–8, 163–4, 166–7, 170, 173
side-effects 156, 162–4, 166, 168–70, 172–4
suicidality 156–7, 173
trazodone 158–9, 161, 166–70
venlafaxine 158–9, 161, 170–3
NSAID see nonsteroidal anti-inflammatory drugs
NTD see neural tube defects
number needed to harm (NNH) 135, 139–40, 143
number needed to treat (NNT) 135, 142–3
OAS see Overt Aggression Scale
obesity 367
obsessive compulsive disorder (OCD) antidepressants 105, 107, 109, 131, 137, 139–42
anxiolytics 311–12, 320
combination pharmacotherapy 421–2, 433–4
complementary and alternative medications 376, 378, 386
memantine 368
novel antidepressants 156–7
off-label use 32
preschool psychotropic medication
use 411–12, 414
riluzole 370
topiramate 372
ODD see oppositional defiant disorder
off-label use 25–38
context and regulatory factors 25–7,
31–4
FDA minimum age use guidelines
29–30
forms and examples 26
generic drugs 41–2
incidence and prevalence 27–31
pharmacoepidemiology 12–13
preschool psychotropic medication
use 406
recommendations 35–6
omega-3 fatty acids 175, 383–4
opiate antagonists 365–8
oppositional defiant disorder (ODD)
antipsychotics 188
comorbidities 77–8, 92–3, 226
preschool psychotropic medication
use 409–10, 413
orthostatic hypotension 169
overdose
adrenergic agents 354
antidepressants 115–16, 122
anxiolytics 324
overmedication 3
Overt Aggression Scale (OAS) 239
oxcarbazepine 263–4, 271, 275–9, 287
oxidative stress 381
P-glycoprotein 52–3
pain
antidepressants 111–12
novel antidepressants 163
off-label use 34
Panax spp. (ginseng) 377
panic disorder
antidepressants 105, 118, 144–5
anxiolytics 307–9
complementary and alternative
medications 376, 378
PANSS see Positive and Negative
Syndrome Scale
PAPA see Preschool Age Psychiatric
Assessment
parasomnias 318–19
Parent Child Interaction Therapy
(PCIT) 403, 410, 412
patient adherence/compliance 117
PCIT see Parent Child Interaction
Therapy
PCOS see polycystic ovarian syndrome
PDD see pervasive developmental
disorders
pediatric bipolar disorder see bipolar
disorder
Pedi atric Research Equity Act (PREA)
45–6, 48
performance anxiety 357
persistence see long-term usage
pervasive developmental disorders
(PDD)
adrenergic agents 341, 348, 352, 355
anticonvulsants 266
antipsychotics 185, 188–9, 191,
202–4, 207, 211
combination pharmacotherapy 434
preschool psychotropic medication
use 406–8, 413
see also autism spectrum disorders
PET see positron emission tomography
PFC see prefrontal cortex
pharmacodynamics 39–41, 48, 157–8
pharmacoepidemiology 7–23
alpha-agonists 11, 14–15, 18
antidepressants 11–13
antipsychotics 13–14
concomitant psychotropic medication
15–16, 18
database types 7–8
international patterns of use 17–18
mood stabilizers 15, 18
multiple class studies 17
new methods 8
nonstimulants for ADHD 11
off-label use 12–13
preschool psychotropic medication
use 17
prevalence and trends in prescribing
practices 8–12
psychostimulants 8–11, 66
strengths 8
Index

pharmacogenetics
attention-deficit hyperactivity disorder 93–4
clinical pharmacology 56–8
psychostimulants 93–4
pharmacokinetics
absorption and bioavailability 52–3, 55
adrenergic agents 343, 356
antidepressants 106, 131–4
antipsychotics 184, 196, 200, 208–10
anxiolytics 302–4, 305
clearance 53–4, 55, 59, 60
clinical pharmacology 52–5, 59–60
distribution 53
elimination half-life 54
generic drugs 39–41, 48
initiation and titration 133–4
lithium 241
metabolism 56–8
novel antidepressants 157–8, 163–4, 166–7, 170, 173
pharmacology see clinical pharmacology
phenothiazines 245
phosphoinositide-3-kinase (PIK) pathway 223, 276
phosphokinase C (PKC) 223
photosensitivity 382
physical examinations
antidepressants 112
novel antidepressants 159, 173–4
preschool psychotropic medication use 405
PK see phosphoinositide-3-kinase
pineal gland disorders 382
Piper methysticum (kava kava) 379
PKC see phosphokinase C
plasma protein binding 262–3
play skills 400–1
polycystic ovarian syndrome (PCOS) 269
Positive and Negative Syndrome Scale (PANSS) 201, 206, 208, 211, 266
positron emission tomography (PET) 65, 67–8
postmarketing safety data 85–6
posttraumatic stress disorder (PTSD)
adrenergic agents 357
anticonvulsants 267
antidepressants 145
anxiolytics 310–11, 320
novel antidepressants 165
off-label use 27
preschool psychotropic medication use 412, 414
topiramate 373
Prader–Willi syndrome 367
PREA see Pediatric Research Equity Act
prefrontal cortex (PFC) 67, 70–1
pregnancy
anticonvulsants 270, 274, 278–9
anxiolytics 331
complementary and alternative medications 384
lithium 245–6
novel antidepressants 157
off-label use 27
premature births 270
Preschool Age Psychiatric Assessment (PAPA) 402
preschool psychotropic medication use 399–420
administration and monitoring 404–5
age-appropriate assessments 400–2
anxiety disorders 411–15
attention-deficit/hyperactivity disorder 404, 407–9, 413
context 399–400
developmental considerations 400–2
disruptive behavior disorders 409–10, 413
first line situations 404
generalized anxiety disorder 412–14
major depressive disorder 410, 413
obsessive compulsive disorder 411–12, 414
off-label use 28–31, 406
pharmacoepidemiology 17
posttraumatic stress disorder 412, 414
psychotherapy and CBT 403, 410–12
rise in psychopharmacology use 402
separation anxiety disorder 412–14
sleep disorders 414–15
unique factors 401–2
prescribing and dispensing 113
priapism 169
prodromata 1, 4
psychodynamic psychotherapy 142
psychoeducation 414–15
psychostimulants 65–104
behavior rating scales 82–3
cardiovascular effects 86–7, 91–2
clinical pharmacology 54
clinical use 79–84
combination pharmacotherapy 422, 427–8, 431–4
comorbidities 77–8, 92–3
dosing and administration 79–84
growth suppression 88
long-term efficacy studies 76–9
mechanism of action 65–7
molecular structures 66–7
neuroimaging studies 65, 67–72
nonstimulant ADHD medication comparison 89–92
off-label use 28
pharmacoepidemiology 9–11, 66
pharmacogenetics 93–4
preschool psychotropic medication use 406–9
rebound effects 83–4
short-term efficacy studies 72–5
side-effects and adverse outcomes 84–9
substance abuse and diversion 88–9
psychotherapy
anxiety disorders 142
major depressive disorder 134–6, 145
preschool psychotropic medication use 403, 410, 412
psychotic episodes 237, 422, 424–5
see also antipsychotics
PTSD see post-traumatic stress disorder
quantitative electroencephalography (QEEG) 69
race/ethnicity 9, 12–13, 15, 273–4
radionuclide imaging 65, 67–8
rebound effects
adrenergic agents 354
anxiolytics 316, 331
psychostimulants 83–4
reference listed drugs (RLD) 42, 47
regulatory factors 25–7, 31–4, 39–48
REM behavior disorder 319
riluzole 369–71
risk-taking behaviors 226–7
RLD see reference listed drugs
s-Adenosyl methionine (SAMe) 175, 380
SAD see separation anxiety disorder
SAE see serious adverse events
St John’s wort 58, 175, 384–7
SAMe see s-Adenosyl methionine
Schedule for Affective Disorders and Schizophrenia (K-SADS) 136–7, 233–4
schizophrenia
historical perspectives 1
off-label use 27
topiramate 372–3
school refusal 108–9, 309–10
second-generation antipsychotics (SGA) 2, 235
secretin 371–2
sedative effects 323, 330–2, 348–9
seizures
anxiolytics 323
complementary and alternative medications 383
novel antidepressants 162
selective serotonin and norepinephrine reuptake inhibitors (SSNRI) 158–9, 161–4, 170–4, 245
selective serotonin reuptake inhibitors (SSRI) 131–54
anxiety disorders 308, 310
clinical pharmacology 53–4, 58–9
combination pharmacotherapy 421, 429, 433–4
drug interactions 245
drug monitoring 147, 149
historical perspectives 2
indications and efficacy 105, 108, 110, 118–19, 131, 134–45, 155
initiation and titration 133–4
lithium augmentation 238
long-term usage 148–9
off-label use 28, 30–2
pharmacoepidemiology 12–13
pharmacokinetics 131–4
Index

selective serotonin reuptake inhibitors (SSRI) (Continued)
  preschool psychotropic medication use 402, 407, 410, 411–12
  side-effects 133–4, 146–9
  suicidality 147–8
  withdrawal symptoms 145
self-injurious behavior (SIB) 366–7
separation anxiety disorder (SAD) antidepressants 108–9, 142–4
anxiolytics 309–10
  preschool psychotropic medication use 412–14
serotonergic syndrome 121
serotonin 105–6, 182–3, 206
SET-C see Social Effectiveness Therapy for Children
severe mood dysregulation (SMD) 238
sexual disorders 169, 269
SGA see second-generation antipsychotics
short-term efficacy studies 72–5
SIB see self-injurious behavior
single positron emission computed tomography (SPECT) 68
situational anxiety 312–13
SJS see Stevens–Johnson syndrome
sleep disorders
  adrenergic agents 348–9
  anxiolytics 314–20
  complementary and alternative medications 382–3, 387–8
SMD see severe mood dysregulation
smoking cessation 160–1
social anxiety disorder 312
Social Effectiveness Therapy for Children (SET-C) 143
social phobia
  antidepressants 118, 142–4
  complementary and alternative medications 376
  novel antidepressants 161, 165
socioeconomic factors 9, 12–16
somnambulism 318–19
somnolence 114
spaciness 323
SPECT see single positron emission computed tomography
  spontaneous abortions 270
SSNRI see selective serotonin and norepinephrine reuptake inhibitors
SSRI see selective serotonin reuptake inhibitors
statins 28
Stevens–Johnson syndrome (SJS) 273, 283
stimulants see psychostimulants
sub-threshold bipolar disorder 229–30
substance abuse
  adrenergic agents 341
  complementary and alternative medications 379
  psychostimulants 88–9
  sudden deaths 86–7, 115
suicidality
  antidepressants 147–8
  historical perspectives 2–3
  novel antidepressants 156–7, 173
  pharmacoepidemiology 12
TCA see tricyclic antidepressants
Teacher Report Forms (TRF) 400
teratogenicity 245–6, 270, 278–9
theophylline 245
therapeutic index
  drug interactions 58
  lithium 221
  psychostimulants 79
thyroid augmentation 428–9
thyroid function 242, 243, 248–50
tic disorders
  adrenergic agents 341, 346, 351
  antipsychotics 184, 190–1, 193–4, 196, 204, 208–11
  anxiolytics 314, 323, 331
  combination pharmacotherapy 434
  comorbidities 92
  novel antidepressants 159, 168
  off-label use 32
Tourette’s disorder
  adrenergic agents 341, 347–8, 354–5
  antipsychotics 184, 190–1, 193–4, 196, 204, 208–11
  anxiolytics 314
  combination pharmacotherapy 434
  novel antidepressants 168
  off-label use 32
toxic epidermal necrolysis 273, 283
toxicity
  anticonvulsants 267–8, 270–1, 274–5, 279, 283–4
  lithium 246–7
transdermal patches 342–5
trauma-focused psychotherapies 145
trazodone 158–9, 161, 166–70
treatment resistant depression 117, 139, 171–2
tremor 359
TRF see Teacher Report Forms
trichotillomania 109–10, 379
tricyclic antidepressants (TCA) 105–16
  abuse potential 116
  attention-deficit hyperactivity disorder 90
  chemical properties 105–6
  combination pharmacotherapy 429–31
  context and historical perspective 105
  drug interactions 245
  drug interactions and contraindications 116
  indications 105, 106–12, 122–3
  initiating, maintaining and withdrawing treatment 112–13
  lithium augmentation 238
  overdose 115–16
  pharmacoepidemiology 12–13
side-effects 113–15, 122–3, 156
  tests and examinations 112–13
  typical antipsychotics see antipsychotics
  tyramine pressor effects 121
ultra-high risk (UHR) criteria 3, 212
unipolar depression see depression; major depressive disorder
Valeriana officinalis (valerian) 387–8
  valproate 231, 234, 261–71, 287, 423–5
  venlafaxine 158–9, 161, 170–3
  vitamin B8 378
  voltage-gated sodium channels 264, 276, 279, 285
weight gain 2
  anticonvulsants 268, 286
  antidepressants 114, 119
  combination pharmacotherapy 426–7
  preschool psychotropic medication use 405
weight loss 405
withdrawal symptoms
  antidepressants 113, 120, 145
  anxiolytics 331, 332
  novel antidepressants 159, 162
Young Mania Rating Scale (YMRS) 202, 207–10
  anticonvulsants 265–6, 272, 280
  combination pharmacotherapy 425
  lithium 234